检索结果 - Kim Monkhorst

Refine Results
  1. 1
    X Inactivation Counting and Choice Is a Stochastic Process: Evidence for Involvement of an X-Linked Activator

    X Inactivation Counting and Choice Is a Stochastic Process: Evidence for Involvement of an X-Linked Activator 由 Kim Monkhorst, Iris H. Jonkers, Eveline Rentmeester, Frank Grosveld, Joost Gribnau

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Xist RNA Is Confined to the Nuclear Territory of the Silenced X Chromosome throughout the Cell Cycle

    Xist RNA Is Confined to the Nuclear Territory of the Silenced X Chromosome throughout the Cell Cycle 由 Iris H. Jonkers, Kim Monkhorst, Eveline Rentmeester, J. Anton Grootegoed, Frank Grosveld, Joost Gribnau

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Identification of epithelialization in high transsphincteric fistulas

    Identification of epithelialization in high transsphincteric fistulas 由 Litza E. Mitalas, Robbert S. van Onkelen, Kim Monkhorst, D. D. E. Zimmerman, M. Gosselink, W. R. Schouten

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies

    OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies 由 Josine M.M.F. Quispel-Janssen, Giulia Zago, Robert D. Schouten, Wieneke A. Buikhuisen, Kim Monkhorst, E. Thunissen, Paul Baas

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    RNF12 Is an X-Encoded Dose-Dependent Activator of X Chromosome Inactivation

    RNF12 Is an X-Encoded Dose-Dependent Activator of X Chromosome Inactivation 由 Iris H. Jonkers, Tahsin Stefan Barakat, Eskeatnaf Mulugeta, Kim Monkhorst, Annegien Kenter, Eveline Rentmeester, Frank Grosveld, J. Anton Grootegoed, Joost Gribnau

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin

    SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin 由 Giustina Ferone, Ji‐Ying Song, Kate D. Sutherland, Rajith Bhaskaran, Kim Monkhorst, Jan-Paul Lambooij, Natalie Proost, Gaetano Gargiulo, Anton Berns

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC

    Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC 由 Bianca van Veggel, Adrianus J. de Langen, Sayed M.S. Hashemi, Kim Monkhorst, Daniëlle A.M. Heideman, Erik Thunnissen, Egbert F. Smit

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment

    Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment 由 Adrianus J. de Langen, M. Jebbink, Sayed M.S. Hashemi, Justine L. Kuiper, J. de Bruin-Visser, Kim Monkhorst, Erik Thunnissen, Egbert F. Smit

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer

    Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer 由 Joris van de Haar, Joanne M. Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F. Smit, Lodewyk F.A. Wessels, Edwin Cuppen, Joachim G.J.V. Aerts, Emile E. Voest

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

    Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine 由 Krijn K. Dijkstra, Kim Monkhorst, Luuk J. Schipper, Koen J. Hartemink, Egbert F. Smit, Sovann Kaing, Rosa de Groot, Monika C. Wolkers, Hans Clevers, Edwin Cuppen, Emile E. Voest

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC

    Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC 由 Sophie M. Ernst, Joanne M. Mankor, Job van Riet, Jan H. von der Thüsen, Hendrikus J. Dubbink, Joachim G.J.V. Aerts, Adrianus J. de Langen, Egbert F. Smit, Anne‐Marie C. Dingemans, Kim Monkhorst

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

    Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer 由 Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari, Vincent van der Noort, Jeltje F. de Vries, Joachim G.J.V. Aerts, Daphne W. Dumoulin, Idris Bahce, Anna-Larissa N. Niemeijer, Adrianus J. de Langen, Kim Monkhorst, Paul Baas

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

    Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer 由 Bianca van Veggel, Juliana F. Vilacha Madeira R Santos, Sayed M.S. Hashemi, Marthe S. Paats, Kim Monkhorst, Daniëlle A.M. Heideman, Matthew R. Groves, Teodora Radonic, Egbert F. Smit, Ed Schuuring, Anthonie J. van der Wekken, Adrianus J. de Langen

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Combined deletion of <i>Bap1</i>, <i>Nf2</i>, and <i>Cdkn2ab</i> causes rapid onset of malignant mesothelioma in mice

    Combined deletion of <i>Bap1</i>, <i>Nf2</i>, and <i>Cdkn2ab</i> causes rapid onset of malignant mesothelioma in mice 由 Jitendra Badhai, Gaurav Kumar Pandey, Ji‐Ying Song, Oscar Krijgsman, Rajith Bhaskaran, G. Chandrasekaran, Min‐Chul Kwon, Lorenzo Bombardelli, Kim Monkhorst, Cristoforo Grasso, John Zevenhoven, Jan van der Vliet, Miranda Cozijnsen, Paul Krimpenfort, Daniel S. Peeper, Maarten van Lohuizen, Anton Berns

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

    Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma 由 Josine M.M.F. Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert D. Schouten, Laurel M. Schunselaar, Maria Disselhorst, Houke M. Klomp, Koen J. Hartemink, Sjaak A. Burgers, Wieneke A. Buikhuisen, Paul Baas

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination

    Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination 由 Lieke L. van der Woude, Mark A.J. Gorris, Inge M. N. Wortel, Jeroen H. A. Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grünberg, Michel M. van den Heuvel, Johannes Textor, Carl G. Figdor, Berber Piet, Willemijn S.M.E. Theelen, I. Jolanda M. de Vries

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

    Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC 由 M. Jebbink, Adrianus J. de Langen, Kim Monkhorst, Mirjam C. Boelens, Daan van den Broek, Vincent van der Noort, Cornedine J. de Gooijer, M. Mahn, Anthonie J. van der Wekken, Lizza Hendriks, Sayed M.S. Hashemi, Marthe S. Paats, Anne‐Marie C. Dingemans, Egbert F. Smit

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)

    Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE) 由 Kris G. Samsom, Linda J.W. Bosch, Luuk J. Schipper, Paul Roepman, Ewart de Bruijn, Louisa R. Hoes, Immy Riethorst, Lieke Schoenmaker, Lizet E. van der Kolk, Valesca P. Retèl, Geert Frederix, Tineke E. Buffart, Jacobus J. M. van der Hoeven, Emile E. Voest, Edwin Cuppen, Kim Monkhorst, Gerrit A. Meijer

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

    Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients 由 Ekaterina A. Semenova, Min‐Chul Kwon, Kim Monkhorst, Ji‐Ying Song, Rajith Bhaskaran, Oscar Krijgsman, Thomas Kuilman, Dennis Peters, Wieneke A. Buikhuisen, Egbert F. Smit, Colin E.J. Pritchard, Miranda Cozijnsen, Jan van der Vliet, John Zevenhoven, Jan-Paul Lambooij, Natalie Proost, Erwin van Montfort, Arno Velds, Ivo J. Huijbers, Anton Berns

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

    PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC 由 Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: